akampion News

Please click here to subscribe to regular news updates from the akampioneer.com
Thursday, November 27, 2014

Company News: Publication in Nature Supports ISA Pharmaceuticals´ Synthetic Long Peptide Immunotherapeutic Approach to Treat Cancer

- Synthetic Long Peptide (SLP®) immunotherapy achieves targeted tumor eradication comparable to checkpoint-blocking immunotherapy

- New findings on antigens relevant for checkpoint blocking pave the way for personalized cancer vaccines

ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, today announced that a recent scientific paper in Nature supports the company´s therapeutic approach to using synthetic long peptides in cancer therapy. It could be shown that personalized SLP® immunotherapy is as capable of inducing efficient tumor eradication as are T cell checkpoint inhibitors such as anti-PD-1 and anti-CTLA-4 monoclonal antibodies. The research was conducted by a consortium led by Prof. Robert D. Schreiber from Washington University St. Louis. Prof. Cornelis Melief, Willem-Jan Krebber, and Gwenn E. Mulder from ISA Pharmaceuticals also participated in the project.

Monday, November 24, 2014

Company News: Curetis Closes EUR 14.5 Million Extension of Series B Financing

-      Curetis wins new investors QIAGEN and LSP-HEF, committing EUR 7 million

-      Curetis well financed into 2017

Curetis AG, a developer of next-level molecular diagnostic solutions, today announced it has closed a EUR 14.5 million extension of its Series B financing round, which was originally led by HBM Partners in April 2013. All existing investors – aeris Capital, BioMed Invest, CD Venture, Forbion Capital, HBM Partners, LSP – Life Sciences Partners, Roche Venture Fund, management, a trustee-pool of Curetis employees and private angel investors – participated in the extension financing, investing EUR 7.5 million on a pro rata basis. QIAGEN and LSP Health Economics Fund (LSP-HEF) are joining as new investors, committing a total of EUR 7 million. The financing brings the total amount of equity raised by Curetis AG to over EUR 63.5 million.